GlaxoSmithKline Revenue 2006-2019 | GSK

GlaxoSmithKline annual/quarterly revenue history and growth rate from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • GlaxoSmithKline revenue for the quarter ending June 30, 2019 was $10.040B, a 0.92% increase year-over-year.
  • GlaxoSmithKline revenue for the twelve months ending June 30, 2019 was $37.224B, a 16.03% decline year-over-year.
  • GlaxoSmithKline annual revenue for 2018 was $41.14B, a 5.75% increase from 2017.
  • GlaxoSmithKline annual revenue for 2017 was $38.904B, a 2.93% increase from 2016.
  • GlaxoSmithKline annual revenue for 2016 was $37.798B, a 3.33% increase from 2015.
GlaxoSmithKline Annual Revenue
(Millions of US $)
2018 $41,140
2017 $38,904
2016 $37,798
2015 $36,578
2014 $37,916
2013 $41,475
2012 $41,896
2011 $43,940
2010 $43,903
2009 $44,421
2008 $45,173
2007 $45,455
2006 $42,804
2005 $39,443
GlaxoSmithKline Quarterly Revenue
(Millions of US $)
Q2 2019 $10,040
Q1 2019 $9,978
Q4 2018 $6,661
Q3 2018 $10,544
Q2 2018 $9,949
Q1 2018 $13,986
Q4 2017 $10,128
Q3 2017 $10,268
Q2 2017 $9,361
Q1 2017 $9,147
Q4 2016 $9,595
Q3 2016 $9,905
Q2 2016 $9,373
Q1 2016 $8,925
Q4 2015 $9,617
Q3 2015 $9,498
Q2 2015 $9,020
Q1 2015 $8,512
Q4 2014 $9,319
Q3 2014 $9,120
Q2 2014 $9,472
Q1 2014 $9,440
Q4 2013 $11,235
Q3 2013 $10,518
Q2 2013 $10,166
Q1 2013 $9,875
Q4 2012 $10,782
Q3 2012 $10,512
Q2 2012 $10,210
Q1 2012 $10,717
Q4 2011 $10,990
Q3 2011 $11,304
Q2 2011 $10,950
Q1 2011 $10,544
Q4 2010 $11,636
Q3 2010 $10,560
Q2 2010 $9,196
Q1 2010 $11,286
Q4 2009 $13,218
Q3 2009 $11,097
Q2 2009 $10,527
Q1 2009 $9,734
Q4 2008 $10,522
Q3 2008 $11,158
Q2 2008 $11,689
Q1 2008 $11,247
Q4 2007 $12,116
Q3 2007 $11,067
Q2 2007 $11,263
Q1 2007 $10,927
Q4 2006 $11,417
Q3 2006 $10,645
Q2 2006 $10,696
Q1 2006 $10,198
Q4 2005 $10,363
Q3 2005 $9,770
Q2 2005 $9,538
Q1 2005 $9,561
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $102.412B $41.140B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $344.174B 14.99
Roche Holding AG (RHHBY) Switzerland $241.683B 0.00
Merck (MRK) United States $212.562B 17.48
Pfizer (PFE) United States $201.220B 11.85
Novartis AG (NVS) Switzerland $197.737B 17.02
Novo Nordisk (NVO) Denmark $120.697B 21.33
AstraZeneca (AZN) United Kingdom $114.317B 22.12
Sanofi (SNY) France $111.209B 13.66
Eli Lilly (LLY) United States $108.824B 20.31
AbbVie (ABBV) United States $105.372B 8.44
Bristol-Myers Squibb (BMY) United States $81.559B 11.57
Bayer (BAYRY) Germany $68.561B 9.99
H Lundbeck (HLUYY) Denmark $6.721B 9.70